| Assay ID | Title | Year | Journal | Article |
|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1224789 | Delta TM value showing the stabilisation of PLK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID216627 | In vitro vascular endothelial growth factor receptor 1 inhibitory activity at 2 uM of ATP. | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
| Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID325654 | Inhibition of PI3K | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1529978 | Binding affinity to phosphorylated TTBK1 (unknown origin) by SPR analysis | 2019 | European journal of medicinal chemistry, Jan-01, Volume: 161 | Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. |
| AID1224756 | Delta TM value showing the stabilisation of CAMKK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID152142 | Inhibitory activity against Plasmodium falciparum W2; Not tested | 2003 | Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
| Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases. |
| AID1224761 | Delta TM value showing the stabilisation of CLK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224794 | Delta TM value showing the stabilisation of RSK2b produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224755 | Delta TM value showing the stabilisation of CAMK4 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1529984 | Inhibition of FTK (unknown origin) | 2019 | European journal of medicinal chemistry, Jan-01, Volume: 161 | Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. |
| AID1224776 | Delta TM value showing the stabilisation of ERK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID233585 | Ratio of IC50 of FGFR-1 (FTK) to VEGFR-1 (Flt). | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
| Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID240825 | Inhibition of EPH receptor B2 using ELISA | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. |
| AID1224764 | Delta TM value showing the stabilisation of CK1G1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID72245 | FGFR-1 (FTK) inhibitory activity at 2 uM of ATP in vitro. | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
| Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID1224782 | Delta TM value showing the stabilisation of PAK5 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224758 | Delta TM value showing the stabilisation of CDK6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224804 | Delta TM value showing the stabilisation of VRK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224781 | Delta TM value showing the stabilisation of PAK4 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224784 | Delta TM value showing the stabilisation of PCTK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224793 | Delta TM value showing the stabilisation of RSK2a produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1283956 | Inhibition of human RET cytoplasmic domain (658 to 1114 residues) expressed in baculovirus system preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID233586 | Ratio of IC50 of FGFR-1 (FTK) to VEGFR-2 (KDR). | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
| Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID1730559 | Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by MTT assay | 2021 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 36 | Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments. |
| AID1224783 | Delta TM value showing the stabilisation of PAK6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224775 | Delta TM value showing the stabilisation of ERK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1900240 | Binding affinity to CM5 sensor chip immobilized C-terminal His6/TEV fused-GST-tagged human TTBK1 (14 to 313 residues) expressed in baculovirus infected Sf9 insect cells assessed as dissociation constant measured after 180 secs by surface plasmon resonance | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
| TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. |
| AID1224802 | Delta TM value showing the stabilisation of TNIK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID55537 | Inhibitory activity against Plasmodium falciparum cyclin dependent protein kinase, Pfmrk | 2003 | Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
| Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases. |
| AID1224772 | Delta TM value showing the stabilisation of MAP2K6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID152131 | Inhibitory activity against Plasmodium falciparum D6; Not tested | 2003 | Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
| Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases. |
| AID1224754 | Delta TM value showing the stabilisation of CAMK2G produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224762 | Delta TM value showing the stabilisation of CLK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224785 | Delta TM value showing the stabilisation of PDK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224774 | Delta TM value showing the stabilisation of p38beta produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID238118 | Equilibrium binding constant for EPH receptor B2 | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. |
| AID1224790 | Delta TM value showing the stabilisation of PLK4 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID325605 | Inhibition of Cdk2 | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224799 | Delta TM value showing the stabilisation of NDR1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224778 | Delta TM value showing the stabilisation of NEK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224750 | Delta TM value showing the stabilisation of CAMK1G produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1283957 | Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID1224788 | Delta TM value showing the stabilisation of PIM3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1283961 | Selectivity ratio of IC50 for KDR inhibition (unknown origin) expressed in mouse BA/F3 cells to IC50 for KIF5B/RET inhibition (unknown origin) expressed in mouse BA/F3 cells | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID1224760 | Delta TM value showing the stabilisation of CHEK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1730560 | Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by MTT assay | 2021 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 36 | Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments. |
| AID1224791 | Delta TM value showing the stabilisation of PRKACA produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID290408 | Inhibition of KDR | 2007 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8
| Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. |
| AID1224801 | Delta TM value showing the stabilisation of MST1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224749 | Delta TM value showing the stabilisation of CAMK1D produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224787 | Delta TM value showing the stabilisation of PIM2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224748 | Delta TM value showing the stabilisation of AMPKA2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1529983 | Inhibition of KDR (unknown origin) | 2019 | European journal of medicinal chemistry, Jan-01, Volume: 161 | Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. |
| AID1224807 | Delta TM value showing the stabilisation of YSK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224806 | Delta TM value showing the stabilisation of VRK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1283958 | Selectivity ratio of IC50 for recombinant His-tagged human KDR expressed in insect Sf21 cells to IC50 for human RET cytoplasmic domain (658 to 1114 residues) expressed in baculovirus system | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID1224770 | Delta TM value showing the stabilisation of JAK1~B produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224753 | Delta TM value showing the stabilisation of CAMK2D produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224779 | Delta TM value showing the stabilisation of NEK6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224796 | Delta TM value showing the stabilisation of LOK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224805 | Delta TM value showing the stabilisation of VRK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224769 | Delta TM value showing the stabilisation of GSK3B produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224786 | Delta TM value showing the stabilisation of PIM1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1283963 | Cytotoxicity in mouse BA/F3 cells after 48 hrs by Cell titre glo-based luminescence assay | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID1283959 | Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID1224773 | Delta TM value showing the stabilisation of ASK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224751 | Delta TM value showing the stabilisation of CAMK2A produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224768 | Delta TM value showing the stabilisation of DMPK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224797 | Delta TM value showing the stabilisation of MPSK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224752 | Delta TM value showing the stabilisation of CAMK2B produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224800 | Delta TM value showing the stabilisation of MST4 (2) produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224763 | Delta TM value showing the stabilisation of CLK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224766 | Delta TM value showing the stabilisation of CK1G3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224780 | Delta TM value showing the stabilisation of OSR1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224759 | Delta TM value showing the stabilisation of CDKL1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224767 | Delta TM value showing the stabilisation of DAPK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID238116 | Binding constant for EphB2 tyrosine kinase | 2004 | Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
| Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 1. Comparison with conventional ELISA. |
| AID1529979 | Binding affinity to phosphorylated TTBK1 (unknown origin) assessed as association rate constant by SPR analysis | 2019 | European journal of medicinal chemistry, Jan-01, Volume: 161 | Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. |
| AID241428 | Inhibition of EphB2 receptor tyrosine kinase in ELISA assay | 2004 | Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
| Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 1. Comparison with conventional ELISA. |
| AID1224803 | Delta TM value showing the stabilisation of PBK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224771 | Delta TM value showing the stabilisation of MEK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1730558 | Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay | 2021 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 36 | Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments. |
| AID1529982 | Inhibition of FLT (unknown origin) | 2019 | European journal of medicinal chemistry, Jan-01, Volume: 161 | Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. |
| AID1224777 | Delta TM value showing the stabilisation of MST4(1) produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1283962 | Intrinsic clearance in iv dosed CD1 mouse assessed per 10'6 cells by LC-MS/MS analysis | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID1224765 | Delta TM value showing the stabilisation of CK1G2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1283960 | Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID1224792 | Delta TM value showing the stabilisation of RIOK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID243492 | Inhibition of ephrin-B1-mediated EPH receptor B2 autophosphorylation | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. |
| AID1224757 | Delta TM value showing the stabilisation of CDK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID216644 | Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro. | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
| Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID1224798 | Delta TM value showing the stabilisation of DRAK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224795 | Delta TM value showing the stabilisation of SLK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1795652 | VEGF-R Kinase Inhibition Assay from Article 10.1021/jm990345w: \\Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.\\ | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
| Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2013 | ChemMedChem, Nov, Volume: 8, Issue:11
| X-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2000 | Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
| Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2000 | Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
| Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |